Cargando…
1647TiP Antiandrogen therapy and TMPRSS2 status: How prostate cancer patients are protected from COVID-19 pandemic
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454317/ http://dx.doi.org/10.1016/j.annonc.2021.08.1640 |
| _version_ | 1784570460847996928 |
|---|---|
| author | Claps, M. Jachetti, E. Ferri, R. Badenchini, F. Verzoni, E. Montone, R. Sepe, P. Guadalupi, V. Ottini, A. Baciarello, G. Valdagni, R. Colombo, M.P. de Braud, F. Procopio, G. |
| author_facet | Claps, M. Jachetti, E. Ferri, R. Badenchini, F. Verzoni, E. Montone, R. Sepe, P. Guadalupi, V. Ottini, A. Baciarello, G. Valdagni, R. Colombo, M.P. de Braud, F. Procopio, G. |
| author_sort | Claps, M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8454317 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | European Society for Medical Oncology. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84543172021-09-21 1647TiP Antiandrogen therapy and TMPRSS2 status: How prostate cancer patients are protected from COVID-19 pandemic Claps, M. Jachetti, E. Ferri, R. Badenchini, F. Verzoni, E. Montone, R. Sepe, P. Guadalupi, V. Ottini, A. Baciarello, G. Valdagni, R. Colombo, M.P. de Braud, F. Procopio, G. Ann Oncol Article European Society for Medical Oncology. Published by Elsevier Ltd. 2021-09 2021-09-21 /pmc/articles/PMC8454317/ http://dx.doi.org/10.1016/j.annonc.2021.08.1640 Text en Copyright © 2021 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Claps, M. Jachetti, E. Ferri, R. Badenchini, F. Verzoni, E. Montone, R. Sepe, P. Guadalupi, V. Ottini, A. Baciarello, G. Valdagni, R. Colombo, M.P. de Braud, F. Procopio, G. 1647TiP Antiandrogen therapy and TMPRSS2 status: How prostate cancer patients are protected from COVID-19 pandemic |
| title | 1647TiP Antiandrogen therapy and TMPRSS2 status: How prostate cancer patients are protected from COVID-19 pandemic |
| title_full | 1647TiP Antiandrogen therapy and TMPRSS2 status: How prostate cancer patients are protected from COVID-19 pandemic |
| title_fullStr | 1647TiP Antiandrogen therapy and TMPRSS2 status: How prostate cancer patients are protected from COVID-19 pandemic |
| title_full_unstemmed | 1647TiP Antiandrogen therapy and TMPRSS2 status: How prostate cancer patients are protected from COVID-19 pandemic |
| title_short | 1647TiP Antiandrogen therapy and TMPRSS2 status: How prostate cancer patients are protected from COVID-19 pandemic |
| title_sort | 1647tip antiandrogen therapy and tmprss2 status: how prostate cancer patients are protected from covid-19 pandemic |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454317/ http://dx.doi.org/10.1016/j.annonc.2021.08.1640 |
| work_keys_str_mv | AT clapsm 1647tipantiandrogentherapyandtmprss2statushowprostatecancerpatientsareprotectedfromcovid19pandemic AT jachettie 1647tipantiandrogentherapyandtmprss2statushowprostatecancerpatientsareprotectedfromcovid19pandemic AT ferrir 1647tipantiandrogentherapyandtmprss2statushowprostatecancerpatientsareprotectedfromcovid19pandemic AT badenchinif 1647tipantiandrogentherapyandtmprss2statushowprostatecancerpatientsareprotectedfromcovid19pandemic AT verzonie 1647tipantiandrogentherapyandtmprss2statushowprostatecancerpatientsareprotectedfromcovid19pandemic AT montoner 1647tipantiandrogentherapyandtmprss2statushowprostatecancerpatientsareprotectedfromcovid19pandemic AT sepep 1647tipantiandrogentherapyandtmprss2statushowprostatecancerpatientsareprotectedfromcovid19pandemic AT guadalupiv 1647tipantiandrogentherapyandtmprss2statushowprostatecancerpatientsareprotectedfromcovid19pandemic AT ottinia 1647tipantiandrogentherapyandtmprss2statushowprostatecancerpatientsareprotectedfromcovid19pandemic AT baciarellog 1647tipantiandrogentherapyandtmprss2statushowprostatecancerpatientsareprotectedfromcovid19pandemic AT valdagnir 1647tipantiandrogentherapyandtmprss2statushowprostatecancerpatientsareprotectedfromcovid19pandemic AT colombomp 1647tipantiandrogentherapyandtmprss2statushowprostatecancerpatientsareprotectedfromcovid19pandemic AT debraudf 1647tipantiandrogentherapyandtmprss2statushowprostatecancerpatientsareprotectedfromcovid19pandemic AT procopiog 1647tipantiandrogentherapyandtmprss2statushowprostatecancerpatientsareprotectedfromcovid19pandemic |